146 related articles for article (PubMed ID: 22740943)
1. Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.
Takakura A; Kurita A; Asahara T; Yokoba M; Yamamoto M; Ryuge S; Igawa S; Yasuzawa Y; Sasaki J; Kobayashi H; Masuda N
Oncol Lett; 2012 Mar; 3(3):520-524. PubMed ID: 22740943
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
[TBL] [Abstract][Full Text] [Related]
3. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
4. Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: A new concept.
Martha L; Nakata A; Furuya S; Liu W; Zhang X; Mizoi K; Ogihara T
Biochem Biophys Res Commun; 2023 Jul; 665():19-25. PubMed ID: 37148742
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
6. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
8. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
[TBL] [Abstract][Full Text] [Related]
9. Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.
Hirose K; Kozu C; Yamashita K; Maruo E; Kitamura M; Hasegawa J; Omoda K; Murakami T; Maeda Y
Oncol Lett; 2012 Mar; 3(3):694-698. PubMed ID: 22740978
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
[TBL] [Abstract][Full Text] [Related]
11. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
13. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
[TBL] [Abstract][Full Text] [Related]
16. The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.
Kodawara T; Higashi T; Negoro Y; Kamitani Y; Igarashi T; Watanabe K; Tsukamoto H; Yano R; Masada M; Iwasaki H; Nakamura T
Basic Clin Pharmacol Toxicol; 2016 May; 118(5):333-7. PubMed ID: 26518357
[TBL] [Abstract][Full Text] [Related]
17. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
Kurita A; Kaneda N
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):335-44. PubMed ID: 10219676
[TBL] [Abstract][Full Text] [Related]
18. A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.
Ahmad S; Hughes MA; Lane KT; Redinbo MR; Yeh LA; Scott JE
Curr Chem Genomics; 2011; 5():13-20. PubMed ID: 21643506
[TBL] [Abstract][Full Text] [Related]
19. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
20. Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.
Guan HY; Li PF; Wang XM; Yue JJ; He Y; Luo XM; Su MF; Liao SG; Shi Y
Front Pharmacol; 2017; 8():769. PubMed ID: 29163158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
